LTR Pharma LimitedASX: LTP

Investor Webinar Presentation

Oct 5, 2026 at 5:39 PM EDT · Issued by LTR Pharma Limited via ASX

Filed with ASX · Oct 5, 2026 at 5:39 PM EDT

On 6ix: 6ix.com/news/investor-webinar-presentation-42

Investor Webinar1Final Phase II ResultsReal-World EvidenceROXUS® U.S. UpdateOctober 2026Lee Rodne, Executive ChairmanProfessor Geoffrey Strange, Chief Medical OfficerMelissa Hadley Barrett, Nurse Practitioner and Sexologist, Director, Restorative Health ClinicProfessor Geoffrey StrangeLTR Pharma...

View Attachment

6ix hasn’t read this filing yet.

LTR Pharma Limited on 6ix

Earlier from LTR Pharma

First ROXUS Prescriptions Fulfilled in the United StatesOct 5
Clinical and Commercial Update - Investor WebinarOct 1
SPONTAN Phase II Final ResultsSep 30
Notice of Annual General Meeting/Proxy FormSep 22
Application for quotation of securities - LTPSep 11

Later from LTR Pharma

Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.Oct 7
SPONTAN passes 2,000 dispensed units in AustraliaOct 20
SPONTAN to be Evaluated in Pulmonary Arterial HypertensionOct 21
AGM PresentationOct 22
Results of MeetingOct 23

All LTR Pharma news releases